225 related articles for article (PubMed ID: 32816202)
41. Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer.
Wasifuddin M; Ilerhunmwuwa NP; Becerra H; Hakobyan N; Wasifuddin S; Asadi HA; Wang JC
J Chemother; 2024 Jan; ():1-6. PubMed ID: 38234179
[TBL] [Abstract][Full Text] [Related]
42. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
43. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
44. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
[TBL] [Abstract][Full Text] [Related]
45. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
46. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
47. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
48. Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Morcos PN; Liu J; Blumenthal GM; Zhao H
Clin Pharmacol Ther; 2019 Apr; 105(4):826-828. PubMed ID: 30723888
[No Abstract] [Full Text] [Related]
49. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
Haffajee RL; Frank RG
N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
[No Abstract] [Full Text] [Related]
50. Accelerated approval requirements for lurbinectedin.
Benjamin DJ; Prasad V
Lancet Oncol; 2022 May; 23(5):e206. PubMed ID: 35489350
[No Abstract] [Full Text] [Related]
51. New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.
Arrieta O; Zatarain-BarrĂ³n ZL; Cardona AF
Lancet Oncol; 2020 May; 21(5):605-607. PubMed ID: 32224305
[No Abstract] [Full Text] [Related]
52. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
53. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
54. Lurbinectedin-induced thrombocytopenia: the role of body surface area.
Papachristos A; Ratain MJ
Cancer Chemother Pharmacol; 2022 May; 89(5):573-575. PubMed ID: 35362793
[TBL] [Abstract][Full Text] [Related]
55. ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2023 Aug; 15(8):e17313. PubMed ID: 37491889
[TBL] [Abstract][Full Text] [Related]
56. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
57. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
58. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract][Full Text] [Related]
59. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
60. Precision Medicines' Impact on Orphan Drug Designation.
Mueller CM; Rao GR; Miller Needleman KI
Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]